It is conceivable that manipulating BMP4 and/or mTORC1 signaling networks would lead to the development of novel therapeutics for obesity, metabolic syndrome, and NAFLD. The gene discussed is BMP4; the disease is metabolic dysfunction-associated steatotic liver disease.